Alnylam Announces Receipt of Complete Response Letter from U.S. FDA for Supplemental New Drug Application for Patisiran for the Treatment of the Cardiomyopathy of ATTR Amyloidosis

Read more

Alnylam Announces Positive Outcome of FDA Advisory Committee Meeting

Read more

Subscribe to